|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8750
|
|
pubmed:dateCreated |
1991-6-11
|
|
pubmed:abstractText |
In DAB486IL-2 the receptor-binding domain of native diphtheria toxin is replaced by human IL-2 sequences. This recombinant fusion protein is selectively cytotoxic for cells bearing high-affinity IL-2 receptors--eg, leukaemic cells. A patient with chronic lymphocytic leukaemia who did not respond to gamma interferon and conventional antileukaemic drugs has responded to DAB486IL-2.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0140-6736
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
11
|
|
pubmed:volume |
337
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1124-5
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:1674015-Diphtheria Toxin,
pubmed-meshheading:1674015-Drug Administration Schedule,
pubmed-meshheading:1674015-Humans,
pubmed-meshheading:1674015-Injections, Intravenous,
pubmed-meshheading:1674015-Interleukin-2,
pubmed-meshheading:1674015-Leukemia, Lymphocytic, Chronic, B-Cell,
pubmed-meshheading:1674015-Leukocyte Count,
pubmed-meshheading:1674015-Male,
pubmed-meshheading:1674015-Middle Aged,
pubmed-meshheading:1674015-Receptors, Interleukin-2,
pubmed-meshheading:1674015-Recombinant Fusion Proteins,
pubmed-meshheading:1674015-T-Lymphocytes
|
|
pubmed:year |
1991
|
|
pubmed:articleTitle |
Therapeutic effects of genetically engineered toxin (DAB486IL-2) in patient with chronic lymphocytic leukaemia.
|
|
pubmed:affiliation |
Department of Medicine/Hematology, University of Texas Health Science Center, San Antonio 78284-7880.
|
|
pubmed:publicationType |
Journal Article,
Case Reports
|
